Moderna cuts loan interest margins by 75 basis points under amended Ares Capital agreement
- Moderna amended its credit agreement with Ares Capital and participating lenders, effective November 9, 2026.
- Initial and delayed draw term loan margins fall 0.75 percentage points to 4.75% for SOFR-based loans and 3.75% for base-rate loans.
- The loans’ maturity extends from November 24, 2030, to November 24, 2031.
- Availability for $400 million of delayed draw term loan commitments extends from November 24, 2027, to November 24, 2029.
- The remaining $500 million of delayed draw term loan commitments becomes available through November 24, 2029, versus November 24, 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001682852-26-000208), on November 16, 2026, and is solely responsible for the information contained therein.